Dusigitumab

From WikiProjectMed
Jump to navigation Jump to search
Dusigitumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIGF2
Clinical data
ATC code
  • none
Identifiers
CAS Number
  • 1204390-13-5
IUPHAR/BPS
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6372H9824N1700O2016S54
Molar mass144233.81 g·mol−1

Dusigitumab is a human monoclonal antibody designed for the treatment of cancer. It binds to IGF2.[1][2] It was developed by MedImmune, which was acquired by AstraZeneca, using Xenomouse technology licensed from Abgenix.[3] Its development has been discontinued.[2]

References

  1. ^ "Dusigitumab" (PDF). Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association.
  2. ^ a b Osher E, Macaulay VM (August 2019). "Therapeutic Targeting of the IGF Axis". Cells. 8 (8): 895. doi:10.3390/cells8080895. PMC 6721736. PMID 31416218.
  3. ^ "Dusigitumab - MedImmune". AdisInsight. Springer Nature Switzerland AG.